Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?-Reference-Cited by-同舟云学术

Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?

Published:2017-05-23 Issue:8 Volume:72 Page:2326-2333
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Maitre Thomas,Petitjean Grégoire,Chauffour Aurélie,Bernard Christine,El Helali Najoua,Jarlier Vincent,Reibel Florence,Chavanet Pascal,Aubry Alexandra,Veziris Nicolas

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

http://academic.oup.com/jac/article-pdf/72/8/2326/18801437/dkx150.pdf

Reference42 articles.

1. Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance;JAMA,1993

2. Extensively drug-resistant tuberculosis in the United States, 1993-2007;JAMA,2008

3. Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: a cohort analysis of the national case register;Int J Infect Dis,2015

4. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis;Am J Respir Crit Care Med,2010

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MtrAB two-component system is crucial for the intrinsic resistance and virulence ofMycobacterium abscessus;2024-04-05

2. Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis;Clinical Infectious Diseases;2024-02-10

3. Updates in pulmonary drug‐resistant tuberculosis pharmacotherapy: A focus on BPaL and BPaLM;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-01-25

4. The Research Status, Potential Hazards and Toxicological Mechanisms of Fluoroquinolone Antibiotics in the Environment;Antibiotics;2023-06-15

5. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement;The Lancet Infectious Diseases;2023-04